Polymer-based non-viral gene delivery as a concept for the treatment of cancer

被引:36
作者
Halama, Anna [1 ,3 ]
Kulinski, Michat [1 ,4 ]
Librowski, Tadeusz [2 ]
Lochynski, Stanislaw [1 ]
机构
[1] Wroclaw Univ Technol, Dept Bioorgan Chem, PL-50370 Wroclaw, Poland
[2] Jagiellonian Univ, Coll Med, Dept Pharmacodynam, PL-30688 Krakow, Poland
[3] Genome Anal Ctr, German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Expt Genet, D-85764 Neuherberg, Germany
[4] Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany
关键词
cancer; polymers; gene delivery; synthetic vectors; polyplexes; IN-VITRO; POLYETHYLENIMINE/DNA COMPLEXES; TOPOISOMERASE-I; CELL-LINES; POLYPLEXES; VECTORS; VIVO; TRANSFORMATION; NANOCARRIERS; INHIBITORS;
D O I
10.1016/S1734-1140(09)70160-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gene therapy has become a promising technique for the treatment of cancer. Nevertheless, the success of gene therapy depends oil the effectiveness of the vector. The challenge of a gene carrier is to deliver exogenous DNA from the site of administration into the nucleus of the appropriate target cell, Polymer-based vectors are biologically safe, have low production costs and are efficient tools for gene therapy. Although non-degradable polyplexes exhibit high gene expression levels, their application potential is limited due to their inability to be effectively eliminated, which results in cytotoxicity. The development of biodegradable polymers has allowed for high levels of transfection without cytotoxicity. For site-specific targeting of polyplexes, further modifications, such as incorporation of ligands, can be performed. Most expectations have been addressed to polyplexes architecture according it dynamic response with the microenvironment.
引用
收藏
页码:993 / 999
页数:7
相关论文
共 48 条
[1]  
Anwer K, 2000, CRIT REV THER DRUG, V17, P377
[2]   Intracellular route and transcriptional competence of polyethylenimine-DNA complexes [J].
Bieber, T ;
Meissner, W ;
Kostin, S ;
Niemann, A ;
Elsasser, HP .
JOURNAL OF CONTROLLED RELEASE, 2002, 82 (2-3) :441-454
[3]  
Bielawska A, 2001, POL J PHARMACOL, V53, P283
[4]  
Bielawski K, 2004, POL J PHARMACOL, V56, P373
[5]  
Bielawski K, 2001, POL J PHARMACOL, V53, P143
[6]   Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes [J].
Boeckle, Sabine ;
Fahrmeir, Julia ;
Roedl, Wolfgang ;
Ogris, Manfred ;
Wagner, Ernst .
JOURNAL OF CONTROLLED RELEASE, 2006, 112 (02) :240-248
[7]   Side-effects of a systemic injection of linear polyethylenimine-DNA complexes [J].
Chollet, P ;
Favrot, MC ;
Hurbin, A ;
Coll, JL .
JOURNAL OF GENE MEDICINE, 2002, 4 (01) :84-91
[8]  
Demeneix B, 2004, CURR GENE THER, V4, P445
[9]   Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA [J].
Heidel, Jeremy D. ;
Yu, Zhongping ;
Liu, Joanna Yi-Ching ;
Rele, Shyam M. ;
Liang, Yongchao ;
Zeidan, Ryan K. ;
Kornbrust, Douglas J. ;
Davis, Mark E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (14) :5715-5721
[10]   Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo [J].
Heidel, Jeremy D. ;
Liu, Joanna Yi-Ching ;
Yen, Yun ;
Zhou, Bingsen ;
Heale, Bret S. E. ;
Rossi, John J. ;
Bartlett, Derek W. ;
Davis, Mark E. .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2207-2215